"Promising Results: Geneos Cancer Vaccine Shrinks Liver Tumors in Small Trial"

In a small trial, nearly a third of patients with advanced liver cancer who received a personalized vaccine developed by Geneos Therapeutics along with an immunotherapy drug saw their tumors shrink, suggesting that vaccines based on mutations only present in a patient's tumor may boost the immune system's ability to recognize and attack hard-to-treat cancers. The study involved 36 patients with hepatocellular carcinoma, and the combination therapy resulted in a 30.1% tumor shrinkage rate, compared to the typical 12-18% response with immunotherapy alone. Larger trials are being planned to confirm these findings.